Search within Therapeutic Immunology Group Web Site:

Therapeutic Immunology Group (TIG)

Welcome to our Home Page

The Therapeutic Immunology Group is undertaking basic research into the mechanisms of immune tolerance and how these can be harnessed, using monoclonal antibodies (mAbs) and other modern biotherapeutics, to develop clinical treatments for human diseases that involve disregulation or inappropriate reactions of the Immune System such as in autoimmunity or transplant rejection.

The Therapeutic Immunology Group is headed by:

Publication list

E-mail Prof. Waldmann direct

E-mail Prof. Waldmann's secretary (Gillian Hellstrom)

Professor Herman Waldmann

Prof. Waldmann's Curriculum Vitae

Address:
Therapeutic Immunology Group,
Sir William Dunn School of Pathology,
South Parks Road,
Oxford, OX1 3RE
Tel: +44 (0) 1865 275500 (Enquiries)
Fax: +44 (0) 1865 275501

We are principally funded by:

1) The Medical Research Council Program Grant: "Therapeutic Immunoregulation" (recently renewed until 2013).

2) RISET: an integrated project (IP) of the 6th EU-RTD Framework Program on Transplantation Tolerance (now completed).

We are also developing a portfolio of intellectual property that is available for commercial exploitation and licencing through Isis Innovation Ltd and Cambridge Enterprise.

H. Waldmann, S. Cobbold and G. Hale were also co-founders of TolerRx Inc.: a biopharmaceutical company set up in Boston, USA to translate therapeutic induction of tolerance, particularly with CD3 and CD4 antibodies, to the clinic.

TIG is made up of the following Labs:

Links to:
* *
Tolerance Lab * Molecular Lab *

Links to other Web pages of special interest to TIG

Past members of TIG
Info including new E-mail addresses (where available)

"Developing short-term treatments for long-term outcomes"